208 related articles for article (PubMed ID: 9847303)
1. Function of a bovine papillomavirus type 1 exonic splicing suppressor requires a suboptimal upstream 3' splice site.
Zheng ZM; He PJ; Baker CC
J Virol; 1999 Jan; 73(1):29-36. PubMed ID: 9847303
[TBL] [Abstract][Full Text] [Related]
2. Selection of the bovine papillomavirus type 1 nucleotide 3225 3' splice site is regulated through an exonic splicing enhancer and its juxtaposed exonic splicing suppressor.
Zheng ZM; He P; Baker CC
J Virol; 1996 Jul; 70(7):4691-9. PubMed ID: 8676495
[TBL] [Abstract][Full Text] [Related]
3. Optimization of a weak 3' splice site counteracts the function of a bovine papillomavirus type 1 exonic splicing suppressor in vitro and in vivo.
Zheng ZM; Quintero J; Reid ES; Gocke C; Baker CC
J Virol; 2000 Jul; 74(13):5902-10. PubMed ID: 10846071
[TBL] [Abstract][Full Text] [Related]
4. Utilization of the bovine papillomavirus type 1 late-stage-specific nucleotide 3605 3' splice site is modulated by a novel exonic bipartite regulator but not by an intronic purine-rich element.
Zheng ZM; Reid ES; Baker CC
J Virol; 2000 Nov; 74(22):10612-22. PubMed ID: 11044105
[TBL] [Abstract][Full Text] [Related]
5. Structural, functional, and protein binding analyses of bovine papillomavirus type 1 exonic splicing enhancers.
Zheng ZM; He PJ; Baker CC
J Virol; 1997 Dec; 71(12):9096-107. PubMed ID: 9371566
[TBL] [Abstract][Full Text] [Related]
6. A pyrimidine-rich exonic splicing suppressor binds multiple RNA splicing factors and inhibits spliceosome assembly.
Zheng ZM; Huynen M; Baker CC
Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14088-93. PubMed ID: 9826658
[TBL] [Abstract][Full Text] [Related]
7. Exonic splicing enhancer-dependent selection of the bovine papillomavirus type 1 nucleotide 3225 3' splice site can be rescued in a cell lacking splicing factor ASF/SF2 through activation of the phosphatidylinositol 3-kinase/Akt pathway.
Liu X; Mayeda A; Tao M; Zheng ZM
J Virol; 2003 Feb; 77(3):2105-15. PubMed ID: 12525645
[TBL] [Abstract][Full Text] [Related]
8. Exonic splicing enhancers contribute to the use of both 3' and 5' splice site usage of rat beta-tropomyosin pre-mRNA.
Selvakumar M; Helfman DM
RNA; 1999 Mar; 5(3):378-94. PubMed ID: 10094307
[TBL] [Abstract][Full Text] [Related]
9. Sequences homologous to 5' splice sites are required for the inhibitory activity of papillomavirus late 3' untranslated regions.
Furth PA; Choe WT; Rex JH; Byrne JC; Baker CC
Mol Cell Biol; 1994 Aug; 14(8):5278-89. PubMed ID: 8035806
[TBL] [Abstract][Full Text] [Related]
10. Presence of exon splicing silencers within human immunodeficiency virus type 1 tat exon 2 and tat-rev exon 3: evidence for inhibition mediated by cellular factors.
Amendt BA; Si ZH; Stoltzfus CM
Mol Cell Biol; 1995 Aug; 15(8):4606-15. PubMed ID: 7623852
[TBL] [Abstract][Full Text] [Related]
11. Muscle-specific exonic splicing silencer for exon exclusion in human ATP synthase gamma-subunit pre-mRNA.
Hayakawa M; Sakashita E; Ueno E; Tominaga S; Hamamoto T; Kagawa Y; Endo H
J Biol Chem; 2002 Mar; 277(9):6974-84. PubMed ID: 11744705
[TBL] [Abstract][Full Text] [Related]
12. Parameters that affect in vitro splicing of bovine papillomavirus type 1 late pre-mRNAs.
Zheng ZM; Baker CC
J Virol Methods; 2000 Mar; 85(1-2):203-14. PubMed ID: 10716353
[TBL] [Abstract][Full Text] [Related]
13. Splicing efficiency of human immunodeficiency virus type 1 tat RNA is determined by both a suboptimal 3' splice site and a 10 nucleotide exon splicing silencer element located within tat exon 2.
Si Z; Amendt BA; Stoltzfus CM
Nucleic Acids Res; 1997 Feb; 25(4):861-7. PubMed ID: 9016638
[TBL] [Abstract][Full Text] [Related]
14. Splicing regulatory elements within tat exon 2 of human immunodeficiency virus type 1 (HIV-1) are characteristic of group M but not group O HIV-1 strains.
Bilodeau PS; Domsic JK; Stoltzfus CM
J Virol; 1999 Dec; 73(12):9764-72. PubMed ID: 10559286
[TBL] [Abstract][Full Text] [Related]
15. A suboptimal 5' splice site downstream of HIV-1 splice site A1 is required for unspliced viral mRNA accumulation and efficient virus replication.
Madsen JM; Stoltzfus CM
Retrovirology; 2006 Feb; 3():10. PubMed ID: 16457729
[TBL] [Abstract][Full Text] [Related]
16. The strength of the HIV-1 3' splice sites affects Rev function.
Kammler S; Otte M; Hauber I; Kjems J; Hauber J; Schaal H
Retrovirology; 2006 Dec; 3():89. PubMed ID: 17144911
[TBL] [Abstract][Full Text] [Related]
17. Enhancer-dependent 5'-splice site control of fruitless pre-mRNA splicing.
Lam BJ; Bakshi A; Ekinci FY; Webb J; Graveley BR; Hertel KJ
J Biol Chem; 2003 Jun; 278(25):22740-7. PubMed ID: 12646561
[TBL] [Abstract][Full Text] [Related]
18. The conserved dinucleotide AG of the 3' splice site may be recognized twice during in vitro splicing of mammalian mRNA precursors.
Zhuang Y; Weiner AM
Gene; 1990 Jun; 90(2):263-9. PubMed ID: 2401404
[TBL] [Abstract][Full Text] [Related]
19. Role of purine-rich exonic splicing enhancers in nuclear retention of pre-mRNAs.
Taniguchi I; Masuyama K; Ohno M
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13684-9. PubMed ID: 17699631
[TBL] [Abstract][Full Text] [Related]
20. Factors involved in the activation of pre-mRNA splicing from downstream splicing enhancers.
Achsel T; Shimura Y
J Biochem; 1996 Jul; 120(1):53-60. PubMed ID: 8864844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
